Filtered By:
Source: American Heart Journal
Condition: Heart Attack
Education: Study
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 152 results found since Jan 2013.
A Randomized Trial to Compare the Safety of Rivaroxaban versus Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome: The Design of the GEMINI-ACS-1 Phase II Study
Publication date: Available online 18 January 2016 Source:American Heart Journal Author(s): Thomas J. Povsic, Matthew T. Roe, E. Magnus Ohman, Philippe Gabriel Steg, Stefan James, Alexei Plotnikov, Hardi Mundl, Robert Welsh, Christoph Bode, C. Michael Gibson Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for 12 months remains the standard of care after presentation with acute coronary syndrome (ACS) because it has been shown to be associated with a significant reduction in ischemic events compared with aspirin monotherapy. The factor Xa inhibitor rivaroxaban was shown ...
Source: American Heart Journal - January 19, 2016 Category: Cardiology Source Type: research
Rationale and Design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) Trial
Publication date: Available online 21 December 2015 Source:American Heart Journal Author(s): Rury R. Holman, M. Angelyn Bethel, Jyothis George, Harald Sourij, Zoë Doran, Joanne Keenan, Nardev S. Khurmi, Robert J. Mentz, Abderrahim Oulhaj, John B. Buse, Juliana C. Chan, Nayyar Iqbal, Sudeep Kundu, Aldo P. Maggioni, Steven P. Marso, Peter Öhman, Michael J. Pencina, Neil Poulter, Lisa E. Porter, Ambady Ramachandran, Bernard Zinman, Adrian F. Hernandez Exenatide once-weekly is an extended release formulation of exenatide, a glucagon-like peptide (GLP)-1 receptor agonist, which can improve glycemic con...
Source: American Heart Journal - December 22, 2015 Category: Cardiology Source Type: research
Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation
Publication date: Available online 1 December 2015 Source:American Heart Journal Author(s): Vincent Johan Nijenhuis, Naoual Bennaghmouch, Mariella Hassell, Jan Baan, Jan Peter van Kuijk, Pierfrancesco Agostoni, Arnoud van ‘t Hof, Peter C. Kievit, Leo Veenstra, Pim van der Harst, Ad F.M. van den Heuvel, Peter den Heijer, Johannes C. Kelder, Vera H. Deneer, Frank van der Kley, Francesco Onorati, Jean Philippe Collet, Francesco Maisano, Azeem Latib, Kurt Huber, Pieter R. Stella, Jurrien M. ten Berg Background Despite improving experience and techniques, ischemic and bleeding complications after Trans...
Source: American Heart Journal - December 1, 2015 Category: Cardiology Source Type: research
Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trial
Conclusions This exploratory analysis suggests that, in patients who require stenting of a large coronary artery, use of a clinical risk score may identify those patients for whom DES use may confer a clinical advantage over BMS, beyond lower restenosis rates.
Source: American Heart Journal - December 1, 2015 Category: Cardiology Source Type: research
Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock -Design and rationale of CULPRIT-SHOCK trial
Conclusions The CULPRIT-SHOCK trial will address the question of optimal revascularization strategy in patients with multivessel disease and acute myocardial infarction complicated by cardiogenic shock.
Source: American Heart Journal - December 1, 2015 Category: Cardiology Source Type: research
Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS) – Rationale and design of a prospective randomized multicenter study
Conclusion MonDAFIS will be the largest study to date to evaluate whether a prolonged and systematic ECG monitoring during the initial in hospital stay has an impact on secondary stroke prevention. In addition, prognosis as well as adherence to medication up to two years after the index stroke will be analyzed. The primary results of the MonDAFIS study may have the potential to change the current guidelines recommendations regarding ECG work-up after ischemic stroke.
Source: American Heart Journal - October 22, 2015 Category: Cardiology Source Type: research
Interleukin-6 and C-reactive protein and Risk for Death and Cardiovascular Events in Patients with Atrial Fibrillation
Conclusion In patients with AF, IL-6 is related to higher risk of stroke and major bleeding, and both markers are related to higher risk of vascular death and the composite of thromboembolic events independent of clinical risk factors. Adjustment for cardiovascular biomarkers attenuated the prognostic value, although IL-6 remained related to mortality, the composite of thromboembolic events, and major bleeding, and CRP to myocardial infarction.
Source: American Heart Journal - October 4, 2015 Category: Cardiology Source Type: research
Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized with PCI - Rationale and study design of the prospective observational multicenter AVIATOR 2 Registry
Publication date: Available online 21 September 2015 Source:American Heart Journal Author(s): Jaya Chandrasekhar, Ioannis Mastoris, Usman Baber, Samantha Sartori, Mikkel Schoos, Sameer Bansilal, George Dangas, Roxana Mehran Background In the era of novel anti-thrombotic therapy, the optimal treatment for patients with non-valvular atrial fibrillation (AF) or flutter undergoing percutaneous coronary intervention (PCI) is undetermined. Study Design The AVIATOR 2 study is a multicenter prospective observational registry that will enroll approximately 2500 patients with non-valvular AF or flutter undergoing PCI star...
Source: American Heart Journal - September 21, 2015 Category: Cardiology Source Type: research
Assessment of the Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at High-Risk for Vascular Outcomes – Rationale and Design of the ACCELERATE Trial
Conclusions ACCELERATE will establish whether the CETP inhibition by evacetrapib improves cardiovascular outcomes in patients with high risk vascular disease.
Source: American Heart Journal - September 16, 2015 Category: Cardiology Source Type: research
Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation
Conclusions Urinary 11-dehydro-TxB2 levels are associated with a residual risk of CVEs and CV mortality in patients with AF despite anticoagulant treatment.
Source: American Heart Journal - September 15, 2015 Category: Cardiology Source Type: research
High-risk percutaneous coronary intervention is associated with reverse left ventricular remodeling and improved outcomes in patients with coronary artery disease and reduced ejection fraction
Conclusions Reverse LV remodeling can occur after high-risk PCI in patients with complex coronary artery disease and reduced EF and is associated with improved clinical outcomes.
Source: American Heart Journal - September 15, 2015 Category: Cardiology Source Type: research
The Brazilian Cardioprotective Nutritional Program to reduce events and risk factors in secondary prevention for cardiovascular disease: study protocol (The BALANCE Program Trial)
This article reports the rationale for the Brazilian Cardioprotective Nutritional Program (BALANCE Program) Trial. This pragmatic, multicenter, nationwide, randomized, concealed, controlled trial was designed to investigate the effects of the BALANCE Program in reducing cardiovascular events. The BALANCE Program consists of a prescribed diet guided by nutritional content recommendations from Brazilian national guidelines using a unique nutritional education strategy, which includes suggestions of affordable foods. In addition, the Program focuses on intensive follow-up through one-on-one visits, group sessions, and phone c...
Source: American Heart Journal - August 16, 2015 Category: Cardiology Source Type: research
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: Results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial
Conclusion Although considerably less frequent than stroke, systemic embolism is associated with significant morbidity and mortality in patients with AF. Although the overall number of events was too small to show a significant difference in the risk of SEE between edoxaban and warfarin, a meta-analysis of all the NOAC trials demonstrates that NOACs significantly reduce the risk of SEE compared with warfarin.
Source: American Heart Journal - August 6, 2015 Category: Cardiology Source Type: research
Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: optimization of antiplatelet treatment in patients aged 70years and older – Rationale and design of the POPular AGE-study
Conclusion The POPular AGE is the first randomized controlled trial that will assess whether the treatment strategy with clopidogrel will result in fewer bleeding events without compromising the net clinical benefit in patients≥70years of age with NSTE-ACS, when compared with a treatment strategy with ticagrelor or prasugrel.
Source: American Heart Journal - August 5, 2015 Category: Cardiology Source Type: research
Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: from the ACCOAST study
Conclusions In ACCOAST, early (<2.98 days) surgical revascularization carried increased risk of bleeding and ischemic complications without affecting all-cause mortality through 30 days. Baseline troponin and prasugrel pretreatment did not impact ischemic clinical outcomes.
Source: American Heart Journal - July 30, 2015 Category: Cardiology Source Type: research
